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TO THE EDITOR
Being amenable to genetic modifica-
tion, mice are critical in vivo tools to
test the role of gene mutations in
malignant melanoma (MM) develop-
ment. They are the animal model of
choice for studying MM growth and
treatments either as autochthonous tu-
mors or as xenografts. However, adult
mice do not have epidermal melano-
cytes (MCs), and primary murine MMs
are usually dermal, reminiscent of hu-
man malignant blue nevi (see, e.g.,
Dhomen et al., 2009), animal type, or
nodular MM. In contrast, most human
MMs appear to originate in the epider-
mis, although they can progress to a
vertical growth phase and invade the
dermis. Although most murine MMs are
dermal, lesions from the hepatocyte
growth factor model often exhibit epi-
dermal ‘‘pagetoid’’ spread on the albino
(FVB) but not C57BL6 background
(Noonan et al., 2001; Florell et al.,
2007). Focal pagetoid spread is also seen
in PtenF/F::Tyr-CreERT2::LSL-BrafCA/wt mice
(Dankort et al., 2009).
One factor that differentiates mouse
from human skin is the expression of
KIT receptor ligand (KITL), highly ex-
pressed in the human but not murine
epidermis (Kunisada et al., 1998; Longley
and Carter, 1999). It is expressed in
76% of human MMs, not only in
adjacent keratinocytes, but also some-
times in the tumor cells (Giehl et al.,
2007). Mice with engineered keratinocyte
Kitl expression (K14-Kitl) have epidermal
MCs throughout life (Kunisada et al.,
1998). Remarkably, they do not
develop MMs even after chronic UVR
exposures (Yamazaki et al., 2004).
When crossed onto a DNA repair
defective (Xpa-null) background, they
developed lentigo-like lesions (Yama-
zaki et al., 2005) after a harsh chronic
UVR regimen. Although the physiolo-
gical relevance of this study is ques-
tionable, as many animals died from
severe sunburn, epidermal MMs did
develop. Recently, K14-Kitl mice were
crossed with animals carrying activa-
tion of the metabotropic glutamate
receptor-1 (Abdel-Daim et al., 2010),
but only dermal MMs were reported.
We previously reported the devel-
opment of dermal MMs in Arf/::Tyr-Abbreviations: MC, melanocyte; MM, malignant melanoma
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NrasQ61K mice (Ferguson et al., 2010).
These mice develop MMs with early
age of onset (average of 114 days) after
neonatal UVR. We hypothesized that
the same mutations (in Arf and Nras)
should lead to the development of
epidermal MMs in mice with epidermal
MCs. Arf/::Tyr-NrasQ61K::K14-Kitl mice
were exposed to a single neonatal UVB
treatment and followed for the devel-
opment of MMs. Experiments were
undertaken with institute animal ethics
approval. As with K14-Kitl mice, we
observed MCs along the basal layer of
the compound mutants (Figure 1a). The
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Figure 1. Histopathology of superficial spreading melanoma equivalents in Arf/::Tyr-Nras::K14-Kitl mice. (a) Double-label immunofluorescence (IF)
staining for S100 and K14 on ‘‘normal’’ Arf/::Tyr-Nras::K14-Kitl mouse skin (methods fully described in Supplementary Material online). Briefly, sections
of formalin-fixed and paraffin-embedded skin were stained with anti-S100 (Dako, Eli, UK) primary antibody, followed by an AlexaFluor 555-labeled donkey
anti-rabbit secondary antibody (Jackson ImmunoResearch Laboratories, West Grove, PA). After several washes, we stained keratinocytes using anti-K14 (Dako)
followed with AlexaFluor 488-labeled donkey anti-rabbit (Jackson ImmunoResearch Laboratories). The yellow arrow points to red S100 staining MCs sitting at the
dermoepidermal junction. Scale bar¼ 20mM. (b) Hematoxylin and eosin (H&E) staining of bleached formalin-fixed, paraffin-embedded sections of Arf/::Tyr-
Nras::K14-Kitl mouse skin. Bleaching is described in Supplementary Methods online. Note cluster (nest) of atypical MC cells in the epidermis, indicated by a dotted
yellow arrow. Scale bar¼ 20mM. (c) IF staining of a similar portion of epidermis with a dense cluster of S100-positive epidermal MCs (indicated by dotted arrows).
Solid yellow arrow points to a dermal MC. Scale bar¼ 20mM. (d) Epidermal MC cluster stained for S100 and Ki-67. Dotted yellow arrow shows MCs in the
suprabasal epidermis positive for Ki-67. Solid white arrows denote keratinocytes (S100-negative cells) staining for Ki-67. Scale bar¼ 20mM. (e) Arf/::Tyr-
Nras::K14-Kitl mouse with a slightly elevated pigmented plaque on its back. Note that because of the heavy pigmentation of the whole skin, the melanoma is not
easily discernible in this photograph. Mouse background: FVB, two generations down C57BL6. (f) H&E-stained section showing raised plaque. Scale bar¼200mM.
(g) IF staining of a Arf/::Tyr-Nras::K14-Kitl plaque for Tyrp1 (red) and K14 (green). Scale bar¼100mM. (h) Double-layer IF image of a pigmented plaque staining
for F4/80 (red) and S100 (green). Dotted yellow arrows denote macrophage lineage cells (melanophages) in a ‘‘cobblestone’’ pattern. The pigmented part of the
tumor consists of many melanophages interspersed with some melanocytes/melanoma cells. Scale bar¼20mM. (i) Higher-power H&E image of MC nesting in the
thickened epidermis within a plaque. Scale bar¼ 20mM. (j) Higher-power image of IF staining of S100-positive epidermal MCs within an epidermal melanoma.
K14-positive keratinocytes are green. Scale bar¼ 20mM. (k) Double-label IF staining for Tyrp1 using the PEP1 antibody, a gift from Dr Vince Hearing. K14-positive
keratinocytes are green. Whereas S100 IF staining somewhat obscures the 4,6-diamidino-2-phenylindole (DAPI)-stained nuclei, Tyrp1 staining allows better
visualization of MC nuclei of varying sizes and shapes (indicated by white arrows). Scale bar¼20mM.
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hyperpigmented skin was bleached,
and histopathological analysis revealed
nests of MCs in the epidermis and scat-
tered MCs in the dermis (Figure 1b).
We confirmed the epidermal localiza-
tion of MCs by staining with anti-S100
or anti-Tyrp1 antibodies and anti-kera-
tin 14 to stain keratinocytes (Figure 1c).
The presence of the increased numbers
of MCs singly and in small nests in all
levels of the epidermis, some of which
stained for Ki-67 (Figure 1d), is sugges-
tive of early epidermal MM. As MCs
do not normally remain in the adult
murine epidermis, we wanted to deter-
mine how long they survive there when
supported by constitutive Kitl expres-
sion. We performed label retention
experiments beginning with injection
of K14-Kitl neonates with BrdU. When
skin was examined 8 weeks later, many
epidermal MCs still carried label (Sup-
plementary Figure S1a and b online),
indicating that they are slow cycling
and can remain for long periods in the
epidermis. This is consistent with the
MC nests emanating from expansion of
these epidermal MCs rather than inva-
sion of dermal MCs.
By eye, it was not possible to discern
the MC nests from ‘‘normal’’ skin
because of its hyperpigmented nature,
but slightly elevated plaques were also
observed (Figure 1e–k), developing at
an average age of onset of 100 days.
Although this is earlier than Arf/::Tyr-
NrasQ61K lesions (Supplementary Figure
S2 online), the difference may be
because of strain differences between
the cohorts. Critically, whereas Arf/
::Tyr-NrasQ61K mice developed deep
dermal lesions clearly separated from
the epidermis by layers of collagen
(Figure 2a), the plaques developing in
Arf/::Tyr-NrasQ61K::K14-Kitl animals
exhibited an epidermal pagetoid
growth pattern with epidermal hyper-
plasia (Figure 1g–k), as well as spread
within the adjacent dermis (Figure 2b).
The deeper highly pigmented dermal
portion of the plaques contains mostly
melanophages interspersed with scat-
tered MCs (Figure 1h). As atypical MCs
are present within all levels of the
epidermis, and to some extent beneath
the epidermis in the papillary dermis,
there are clear similarities between
these murine lesions and human super-
ficial spreading MMs (Figure 2c).
We also examined skin from other
anatomical locations (Supplementary
Figure S3 a–i online). In the ears and
tail, we saw slightly atypical MCs along
the entire dermoepidermal junction and
to some degree in the dermis. The effect
of keratinocyte Kitl expression was
especially noticeable in the footpads
(Supplementary Figure S3 g–i online). In
Arf/::Tyr-NrasQ61K mice, the footpads
are white with no MCs present (data
not shown). However, Arf/::Tyr-
NrasQ61K::K14-Kitl mice have black
footpads, and histopathology shows
MCs singly, and as nests, throughout
the epidermis. We did not observe
visible plaques on any anatomical
location other than the dorsal skin.
A common criticism of mice as MM
models is the dermal localization of
lesions. Using a dermal murine MM
model, we show that overexpression of
just one cytokine in keratinocytes—
Kitl—essentially translocates MMs into
the epidermis, where they exhibit nest-
ing and pagetoid spread. Hence, it is
likely that many aspects of transfo-
rmation of murine MCs are similar to
those occurring during human MM
progression. It is noteworthy that there
are no good mutation signatures that
differentiate superficial spreading and
nodular MMs. At least in our experi-
mental model, the same mutations
(a complement of mutations commonly
present in human melanomas that
together with neonatal UVR are suffi-
cient for MC transformation) can induce
both MM subtypes. The growth pattern/
localization of the lesions is totally
controlled by a keratinocyte cytokine.
The development of better methods
of specifically targeting mutations to
epidermal MCs in K14-Kitl mice should
engage the full power of the mouse as a
preclinical model to study the mecha-
nisms of epidermal MM growth. Such
models, along with the one we report in
this study, will facilitate improved
in vivo modeling of gene–environment
interactions in MM carcinogenesis in
adult mice.
a b c
Figure 2. Comparative histopathology of murine and human epidermal melanomas. (a) Hematoxylin and eosin (H&E)-stained section showing a deep dermal
malignant melanoma (MM) in an Arf/::Tyr-Nras mouse. The yellow arrow denotes a nodular melanoma composed of sheets of pleomorphic melanocytes
(MCs). This nodular lesion is clearly separated from the epidermis by layers of collagen. (b) MM from an Arf/::Tyr-Nras::K14-Kitl mouse. Dotted yellow arrow
denotes atypical MCs in the epidermis, and filled yellow arrow atypical MCs in the dermis. There is an increased number of MCs, varying in size and shape,
not only at the dermoepidermal junction but also at all levels of the epidermis. (c) Human superficial spreading MM. Dotted yellow arrow denotes atypical
MCs in the epidermis, and filled yellow arrow atypical MCs in the dermis. The morphological similarities between Figure 2b and c are striking. Scale
bars¼ 100mM.
1386 Journal of Investigative Dermatology (2011), Volume 131
GJ Walker et al.
Development of Epidermal MMs in Mice
CONFLICT OF INTEREST
HPS is a shareholder and consultant for Molemap,
Australia. The other authors state no conflict of
interest.
ACKNOWLEDGMENTS
We thank Dr Vince Hearing for the anti-
Tyrp1 antibody. This work was funded by the
National Health & Medical Research Council
(NH&MRC) of Australia and the Cancer Council
of Queensland. GJW is the recipient of a Senior
Research Fellowship from the Cancer Council of
Queensland.
Graeme J. Walker1, H. Peter Soyer2,
Herlina Y. Handoko1, Blake Ferguson1,
Takahiro Kunisada3, Kiarash
Khosrotehrani1,4, Neil F. Box5
and H. Konrad Muller6
1Skin Carcinogenesis Laboratory, Queensland
Institute of Medical Research, Herston,
Queensland, Australia; 2Dermatology Research
Centre, The University of Queensland, School
of Medicine, Princess Alexandra Hospital,
Brisbane, Queensland, Australia; 3Department
of Tissue and Organ Development, Gifu
University Graduate School of Medicine, Gifu,
Japan; 4Experimental Dermatology Group,
University of Queensland Centre for Clinical
Research, Brisbane, Queensland, Australia;
5Department of Dermatology, University of
Colorado Denver, Aurora, Colorado, USA
and 6School of Medicine, University of
Tasmania, Hobart, Tasmania, Australia
E-mail: Graeme.Walker@qimr.edu.au
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online
version of the paper at http://www.nature.com/jid
REFERENCES
Abdel-Daim M, Funasaka Y, Komoto M et al.
(2010) Pharmacogenomics of metabotropic
glutamate receptor subtype 1 and in vivo
malignant melanoma formation. J Dermatol
37:635–46
Dankort D, Curley DP, Cartlidge RA et al. (2009)
Braf(V600E) cooperates with Pten loss to
induce metastatic melanoma. Nat Genet
41:544–52
Dhomen N, Reis-Filho JS, da Rocha Dias S et al.
(2009) Oncogenic Braf induces melanocyte
senescence and melanoma in mice. Cancer
Cell 15:294–303
Ferguson B, Muller HK, Handoko HY et al. (2010)
Differential roles of the pRb and Arf/p53 path-
ways in murine naevus and melanoma genesis.
Pigment Cell Melanoma Res 23:771–80
Florell SR, Thomas J, Grossman D (2007) Predo-
minant formation of heavily pigmented der-
mal melanocytomas resembling ‘animal-type’
melanomas in hepatocyte growth factor
(C57BL/6  C3H)F1 mice following neonatal
UV irradiation. J Cutan Pathol 34:667–74
Giehl KA, Nagele U, Volkenandt M et al.
(2007) Protein expression of melanocyte
growth factors (bFGF, SCF) and their recep-
tors (FGFR-1, c-kit) in nevi and melanoma.
J Cutan Pathol 34:7–14
Kunisada T, Lu SZ, Yoshida H et al. (1998) Murine
cutaneous mastocytosis and epidermal mel-
anocytosis induced by keratinocyte expres-
sion of transgenic stem cell factor. J Exp Med
187:1565–73
Longley BJ, Carter EL (1999) SCF-KIT pathway in
human epidermal melanocyte homeostasis.
J Invest Dermatol 113:139–40
Noonan FP, Recio JA, Takayama H et al. (2001)
Neonatal sunburn and melanoma in mice.
Nature 413:271–2
Yamazaki F, Okamoto H, Miyauchi-Hashimoto H
et al. (2004) XPA gene-deficient, SCF-trans-
genic mice with epidermal melanin are
resistant to UV-induced carcinogenesis.
J Invest Dermatol 123:220–8
Yamazaki F, Okamoto H, Matsumura Y et al. (2005)
Development of a new mouse model (xero-
derma pigmentosum a-deficient, stem cell
factor-transgenic) of ultraviolet B-induced mel-
anoma. J Invest Dermatol 125:521–5
www.jidonline.org 1387
GJ Walker et al.
Development of Epidermal MMs in Mice
